title: MicroRNA-216a: a potential therapeutic target for drug resistance and recurrent of liver cancer.
authors: Institute for Liver Diseases of Anhui Medical University, School of Pharmacy, Anhui Key Laboratory of Bioactivity of Natural Products, Anhui Medical University, Hefei 230032, China. lj@ahmu.edu.cn.
authors: Zhao-Lin
authors: ZL
authors: Chen
authors: Tao-Tao
authors: TT
authors: Ma
authors: Cheng
authors: C
authors: Huang
authors: Tao
authors: T
authors: Xu
authors: Ting-Ting
authors: TT
authors: Hu
authors: Jun
authors: J
authors: Li
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000503:physiopathology; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D035683:MicroRNAs / Q000037:antagonists & inhibitors* / Q000187:drug effects; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000503:physiopathology; D051059:PTEN Phosphohydrolase / Q000502:physiology; D019869:Phosphatidylinositol 3-Kinases / Q000502:physiology; D051057:Proto-Oncogene Proteins c-akt / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D016212:Transforming Growth Factor beta / Q000502:physiology
chemical_list: D000970:Antineoplastic Agents; C575482:MIRN216 microRNA, human; D035683:MicroRNAs; D016212:Transforming Growth Factor beta; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt; D051059:PTEN Phosphohydrolase